What's New
Monitoring Communication – interleukin inhibitors and possible risk of pancreatitis
Medsafe has published a new monitoring communication. The aim is to encourage reporting of any cases where pancreatitis may have been associated with an interleukin inhibitor medicine.
News and Events
| Date | Type | Title |
|---|---|---|
| 10/5/2023 | Monitoring Communication | Interleukin inhibitors and the possible risk of pancreatitis |
| 10/5/2023 | Committees | Comments on agenda items for the 70th meeting of the Medicines Classification Committee |
| 26/4/2023 | Information Leaflet | Stopping antidepressants: be cautious and go slow |
| 26/4/2023 | Monitoring Communication | Review of pholcodine-containing medicines - Provide your feedback by 8 May 2023 |
| 12/4/2023 | Alert Communication | Topiramate use in pregnancy: further restrictions for safety |
| 4/4/2023 | Committees | Medicines Assessment Advisory Committee - Vacancy for an Oncologist or Specialist Clinician |
